11 – 20 of 31
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
(
- Contribution to journal › Article
-
Mark
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
(
- Contribution to journal › Article
- 2016
-
Mark
Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
(
- Contribution to journal › Article
-
Mark
Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
(
- Contribution to journal › Article
- 2015
-
Mark
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
(
- Contribution to journal › Article
-
Mark
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
(
- Contribution to journal › Article
-
Mark
Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
(
- Contribution to journal › Article